Drug:
Reaction: HOSPITALISATION
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26938196 |
JP |
72 | 1 |
Hospitalisation, Cerebral haemorrhage, |
||||
BRIVARACETAM, |
||||
| 102 | 26938416 |
55 | 2 | |
Hospitalisation, |
||||
MYCOPHENOLIC ACID, MYCOPHENILIC ACID, PENICILLIN V POTASSIUM, CLONIDINE, FUROSEMIDE, PREDNISONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FAMOTIDINE, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, |
||||
| 103 | 26938472 |
US |
54 | 1 |
Hospitalisation, |
||||
ABATACEPT, |
||||
| 104 | 26938512 |
US |
2 | |
Hospitalisation, |
||||
SODIUM OXYBATE, SODIUM OXYBATE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, SPIRONOLACTONE, NAPROXEN, NAPROXEN SODIUM, BUPROPION HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE, ERGOCALCIFEROL, MAGNESIUM, MODAFINIL, LORATADINE, LORATADINE ORAL, ENALAPRIL MALEATE, ENALAPRIL, PROPRANOLOL HYDROCHLORIDE, ALBUTEROL SULFATE, |
||||
| 105 | 26938536 |
US |
71 | 2 |
Hospitalisation, Liver disorder, Condition aggravated, Therapy interrupted, Insurance issue, |
||||
RIFAXIMIN, |
||||
| 106 | 26938624 |
2 | ||
Hospitalisation, |
||||
MOMELOTINIB, |
||||
| 107 | 26938647 |
GB |
2 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 108 | 26938652 |
US |
48 | 1 |
Hospitalisation, Product use issue, |
||||
RIFAXIMIN, |
||||
| 109 | 26938655 |
US |
48 | 2 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 110 | 26938800 |
US |
2 | |
Hospitalisation, Off label use, |
||||
CANNABIDIOL, CANNABIDIOL, |
||||
| 111 | 26938862 |
US |
49 | 2 |
Hospitalisation, |
||||
ENASIDENIB MESYLATE, ENTECAVIR, ENTECAVIR ANHYDROUS, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 112 | 26939038 |
US |
2 | |
Hospitalisation, Memory impairment, Bone pain, Product dose omission in error, Product storage error, Product dose omission issue, Incorrect product administration duration, |
||||
ABALOPARATIDE, ABALOPARATIDE, CALCIUM, ERGOCALCIFEROL, AMANTADINE HYDROCHLORIDE, AMLODIPINE BESYLATE, ROMOSOZUMAB-AQQG, FUROSEMIDE, LOSARTAN POTASSIUM, LOSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREGABALIN, TIZANIDINE HYDROCHLORIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CLOPIDOGREL, CLOPIDOGREL BISULFATE, PANTOPRAZOLE SODIUM, |
||||
| 113 | 26939155 |
US |
78 | 2 |
Hospitalisation, Product dose omission issue, Wrong technique in product usage process, Device failure, Unevaluable event, |
||||
ABALOPARATIDE, ROSUVASTATIN, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, IRON, FUROSEMIDE, EMPAGLIFLOZIN, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, PANTOPRAZOLE, SERTRALINE, CETIRIZINE HYDROCHLORIDE, |
||||
| 114 | 26939346 |
US |
2 | |
Hospitalisation, Viral infection, Dyspnoea, |
||||
ABALOPARATIDE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, EPINEPHRINE, ADRENALINUM, |
||||
| 115 | 26939373 |
US |
2 | |
Hospitalisation, Myalgia, Bone pain, Arthralgia, Discomfort, |
||||
ABALOPARATIDE, |
||||
| 116 | 26939536 |
US |
2 | |
Hospitalisation, Emergency care, Bone pain, |
||||
ABALOPARATIDE, |
||||
| 117 | 26939626 |
US |
2 | |
Hospitalisation, Illness, Pollakiuria, Asthenia, Pain, |
||||
ABALOPARATIDE, |
||||
| 118 | 26939641 |
US |
1 | |
Hospitalisation, Emergency care, Pain in extremity, Arthralgia, Pain, |
||||
ABALOPARATIDE, RIMEGEPANT SULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 119 | 26939804 |
EU |
1 | |
Hospitalisation, Thrombocytopenia, Skin toxicity, Adverse drug reaction, Off label use, |
||||
AMIVANTAMAB-VMJW, AMIVANTAMAB-VMJW, OSIMERTINIB, |
||||
| 120 | 26939929 |
US |
3 | 2 |
Hospitalisation, |
||||
ESKETAMINE HYDROCHLORIDE, ESKETAMINE HYDROCHLORIDE, |
||||
| 121 | 26943064 |
22 | 2 | |
Hospitalisation, |
||||
AVACOPAN, |
||||
| 122 | 26943068 |
64 | 1 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 123 | 26943113 |
64 | 1 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 124 | 26943123 |
74 | 1 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 125 | 26943150 |
72 | 1 | |
Hospitalisation, |
||||
MYCOPHENOLIC ACID, MYCOPHENILIC ACID, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, ISAVUCONAZONIUM SULFATE, MAGNESIUM OXIDE, METHOCARBAMOL, METHOCARBAMOL TABLETS, PREDNISONE, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, |
||||
| 126 | 26931243 |
CA |
1 | |
Hospitalisation, |
||||
INFLIXIMAB-AXXQ, |
||||
| 127 | 26931320 |
US |
1 | |
Hospitalisation, |
||||
CANNABIDIOL, |
||||
| 128 | 26931382 |
US |
1 | |
Hospitalisation, |
||||
VALBENAZINE, |
||||
| 129 | 26931792 |
US |
68 | |
Hospitalisation, |
||||
PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, |
||||
| 130 | 26931795 |
US |
||
Hospitalisation, Product use issue, |
||||
CENOBAMATE, CENOBAMATE, |
||||
| 131 | 26931835 |
US |
34 | 2 |
Pulmonary oedema, Syncope, Epistaxis, Headache, Pain, Myocardial infarction, Syncope, Catheter site thrombosis, Respiratory failure, Vascular device infection, Device related infection, Infection, Oedema peripheral, Nausea, Lung disorder, Cardiac disorder, Presyncope, Central venous catheterisation, Pain, Hospitalisation, Blood pressure decreased, Chest pain, Hypotension, Haematological infection, Head injury, Vascular access complication, Weight decreased, Seizure, Pericardial effusion, Pulmonary hypertension, Thrombosis, Complication associated with device, Cellulitis, Haemoglobin decreased, Chills, Hypoaesthesia oral, Tremor, Weight increased, Paraesthesia, Haemorrhage, Flushing, Suture related complication, Foreign body, Suture rupture, Blood creatinine increased, Depression, Dizziness, Dyspnoea exertional, Catheter site irritation, Catheter site pruritus, Infusion site infection, Rash, Vomiting, Syncope, Myocardial infarction, Pain, Complication associated with device, Complication associated with device, Chest pain, Oedema peripheral, Chest pain, Lung disorder, Central venous catheterisation, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, MIDODRINE HYDROCHLORIDE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, OXYGEN, 0XYGEN, OLANZAPINE, ALBUTEROL SULFATE, FLUOXETINE HYDROCHLORIDE, CEFTRIAXONE, CEFTRIAXONE SODIUM, FOLIC ACID, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, FUROSEMIDE, SILDENAFIL CITRATE, SILDENAFIL, METOLAZONE, CEFAZOLIN SODIUM, CLONAZEPAM, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, DULOXETINE HYDROCHLORIDE, OXCARBAZEPINE, ORAL SEMAGLUTIDE, TORSEMIDE, GABAPENTIN, IRON, SELEXIPAG, MORPHINE SULFATE, BUMETANIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, SPIRONOLACTONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, CEFAZOLIN SODIUM, CEFAZOLIN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, WATER, STERILE WATER, STERILE WATER FOR INJECTION, |
||||
| 132 | 26932142 |
US |
2 | |
Hospitalisation, Intestinal obstruction, |
||||
PANCRELIPASE, |
||||
| 133 | 26932170 |
EU |
60 | |
Hospitalisation, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 134 | 26932212 |
US |
48 | 2 |
Hospitalisation, Abdominal distension, Flatulence, Norovirus infection, Colitis, Crohn^s disease, Faeces soft, Dyspnoea, Abdominal pain, |
||||
PANCRELIPASE, PANCRELIPASE, RISANKIZUMAB-RZAA, |
||||
| 135 | 26932293 |
GB |
2 | |
Diarrhoea, Vomiting, Hospitalisation, |
||||
| 136 | 26932541 |
GB |
70 | 2 |
Hospitalisation, |
||||
ENTECAVIR, ENTECAVIR ANHYDROUS, |
||||
| 137 | 26933079 |
CA |
72 | 2 |
Malignant neoplasm progression, Fall, Contusion, Asthenia, Hospitalisation, Muscular weakness, Hypertension, Blood potassium decreased, Angioplasty, Malignant neoplasm progression, Gastric cancer, Headache, Migraine, Myalgia, Abdominal pain, Flatulence, Faeces discoloured, Nausea, Alopecia, Decreased appetite, Weight decreased, Breast discolouration, Insomnia, Pain in extremity, Off label use, Arthralgia, Diarrhoea, Abdominal pain upper, Off label use, Sinusitis, Eye infection, Anaemia, Pancreatic disorder, Vomiting, Nausea, Faeces discoloured, Abdominal pain upper, Polyp, Urinary tract infection, Fatigue, Diarrhoea, Abdominal distension, Stomach mass, Abdominal pain, Nausea, Vomiting, Diarrhoea, Fatigue, Polyp, Diarrhoea, Haemorrhoidal haemorrhage, Pain, Loss of personal independence in daily activities, Conjunctival laceration, Fall, Joint injury, Skin abrasion, Contusion, Pain, Fatigue, Pain, Nausea, Vomiting, Diarrhoea, Fall, Limb injury, Eye irritation, Walking aid user, Entropion, Asthenia, Fatigue, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANSOPRAZOLE, CLONAZEPAM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, CHOLESTYRAMINE, |
||||
| 138 | 26933162 |
US |
74 | 2 |
Atrial fibrillation, Hospitalisation, Hand fracture, Liver disorder, Renal disorder, Ill-defined disorder, |
||||
BRIVARACETAM, |
||||
| 139 | 26933385 |
GB |
86 | 2 |
Hospitalisation, |
||||
PIRFENIDONE, |
||||
| 140 | 26933714 |
CA |
39 | |
Hospitalisation, Dependence, Mental disorder, Heart rate increased, Treatment noncompliance, Off label use, Product dose omission issue, Inappropriate schedule of product administration, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 141 | 26933804 |
US |
44 | 2 |
Hospitalisation, Product use in unapproved indication, |
||||
CAPLACIZUMAB, CAPLACIZUMAB, CAPLACIZUMAB, CAPLACIZUMAB, |
||||
| 142 | 26933945 |
EU |
79 | 2 |
Renal impairment, Hospitalisation, Vertigo, Asthenia, Hypochromic anaemia, Leukocytosis, Pyrexia, Dyspnoea, Oedema, Product use in unapproved indication, |
||||
RIVAROXABAN, |
||||
| 143 | 26934035 |
JP |
50 | 2 |
Hospitalisation, Electrocardiogram QT prolonged, |
||||
ASENAPINE MALEATE, |
||||
| 144 | 26926633 |
US |
89 | 1 |
Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 145 | 26926699 |
US |
2 | |
Hospitalisation, |
||||
EVOLOCUMAB, |
||||
| 146 | 26926940 |
US |
47 | 1 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 147 | 26927190 |
CN |
1 | |
Hospitalisation, |
||||
INSULIN ASPART, |
||||
| 148 | 26927302 |
US |
2 | |
Hospitalisation, Therapy interrupted, |
||||
BRENSOCATIB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CELECOXIB, DONEPEZIL HYDROCHLORIDE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, IPRATROPIUM BROMIDE, ITRACONAZOLE, EMPAGLIFLOZIN, LOSARTAN, MAGNESIUM OXIDE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, PIOGLITAZONE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, RIFAMPIN, ROSUVASTATIN, CINACALCET HYDROCHLORIDE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, ERGOCALCIFEROL, |
||||
| 149 | 26927446 |
US |
40 | 2 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 150 | 26927524 |
AU |
||
Hospitalisation, |
||||
ALBUTEROL SULFATE, |
||||
| 151 | 26927842 |
US |
89 | 2 |
Hospitalisation, |
||||
TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FUROSEMIDE, LISINOPRIL, OXYBUTYNIN, SIMVASTATIN, TIZANIDINE, |
||||
| 152 | 26927958 |
AU |
2 | |
Death, Hospitalisation, |
||||
DENOSUMAB, |
||||
| 153 | 26928049 |
CA |
71 | |
Surgery, Hospitalisation, Femur fracture, Fall, Upper limb fracture, Weight decreased, Intentional dose omission, Product dose omission issue, Underdose, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 154 | 26928501 |
JP |
91 | 2 |
Hospitalisation, |
||||
DARBEPOETIN ALFA, |
||||
| 155 | 26928532 |
US |
84 | 2 |
Death, Hospitalisation, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 156 | 26928593 |
US |
59 | 2 |
Hospitalisation, |
||||
POMALIDOMIDE, |
||||
| 157 | 26928670 |
EU |
44 | 2 |
Hospitalisation, Hallucination, Product dose omission issue, Product temperature excursion issue, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 158 | 26929069 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 159 | 26929142 |
US |
75 | 2 |
Hospitalisation, |
||||
| 160 | 26929412 |
US |
26 | 2 |
Hospitalisation, |
||||
INEBILIZUMAB, INEBILIZUMAB, |
||||
| 161 | 26929461 |
CA |
62 | 2 |
Glioblastoma multiforme, Hospitalisation, Death, Drug ineffective, |
||||
BRIVARACETAM, BRIVARACETAM INJECTION, |
||||
| 162 | 26929554 |
KR |
2 | |
Red blood cell transfusion, Inappropriate schedule of product administration, Hospitalisation, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, |
||||
| 163 | 26929766 |
GB |
1 | |
Hospitalisation, |
||||
IVACAFTOR, |
||||
| 164 | 26930135 |
CA |
41 | 1 |
Hospitalisation, Pain, Therapy interrupted, |
||||
BRODALUMAB, BRODALUMAB, FOLIC ACID, DESONIDE, |
||||
| 165 | 26930248 |
CA |
94 | 1 |
Death, Hospitalisation, |
||||
VENETOCLAX, |
||||
| 166 | 26930785 |
|||
Hospitalisation, |
||||
UPADACITINIB, |
||||
| 167 | 26930847 |
2 | ||
Hospitalisation, |
||||
POMALIDOMIDE, |
||||
| 168 | 26931013 |
1 | ||
Hospitalisation, Therapy interrupted, |
||||
LENALIDOMIDE, ACYCLOVIR, CALCIUM ACETATE, CYANOCOBALAMIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, EPOETIN ALFA, FINASTERIDE, GABAPENTIN, |
||||
| 169 | 26936901 |
68 | 2 | |
Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 170 | 26937161 |
76 | 1 | |
Hospitalisation, |
||||
AVACOPAN, |
||||
| 171 | 26921378 |
US |
55 | 1 |
Hospitalisation, |
||||
ESKETAMINE HYDROCHLORIDE, |
||||
| 172 | 26921587 |
AU |
1 | |
Hospitalisation, Wrong technique in product usage process performed in error, |
||||
ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 173 | 26921676 |
CO |
67 | 2 |
Hospitalisation, |
||||
EVOLOCUMAB, |
||||
| 174 | 26921748 |
EU |
72 | 2 |
Hospitalisation, |
||||
| 175 | 26922037 |
JP |
||
Hospitalisation, |
||||
DAPRODUSTAT, |
||||
| 176 | 26922202 |
JP |
||
Hospitalisation, |
||||
ROTIGOTINE, |
||||
| 177 | 26922318 |
US |
56 | 1 |
Hospitalisation, |
||||
| 178 | 26922381 |
US |
1 | |
Parkinson^s disease, Hospitalisation, Heart rate decreased, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 179 | 26922491 |
GB |
2 | |
Hospitalisation, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 180 | 26922535 |
US |
2 | |
Hospitalisation, |
||||
GLYCEROL PHENYLBUTYRATE, |
||||
| 181 | 26922548 |
US |
||
Hospitalisation, |
||||
CILTACABTAGENE AUTOLEUCEL, |
||||
| 182 | 26922590 |
GB |
54 | 1 |
Hospitalisation, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 183 | 26922591 |
US |
1 | |
Hospitalisation, Off label use, |
||||
| 184 | 26922711 |
EU |
2 | |
Hospitalisation, |
||||
ORAL SEMAGLUTIDE, |
||||
| 185 | 26923225 |
GB |
1 | |
Hospitalisation, |
||||
CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, |
||||
| 186 | 26923277 |
GB |
86 | 2 |
Hospitalisation, |
||||
PIRFENIDONE, |
||||
| 187 | 26924049 |
GB |
1 | |
Hospitalisation, Mental disorder, Dependence, Malaise, Emotional disorder, Cystic fibrosis, Product use issue, |
||||
IVACAFTOR, MANNITOL, DORNASE ALFA, |
||||
| 188 | 26924454 |
US |
13 | 2 |
Hospitalisation, Hospitalisation, Hunger, Electrolyte imbalance, Malnutrition, Nausea, Vomiting, Diarrhoea, |
||||
CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, SUCRALFATE, |
||||
| 189 | 26924519 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 190 | 26924828 |
US |
70 | 1 |
Hospitalisation, |
||||
OLUTASIDENIB, ACYCLOVIR, DIGOXIN, FUROSEMIDE, HEPARIN SODIUM, LOSARTAN, LOVASTATIN, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, FISH OIL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PANTOPRAZOLE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, RIVAROXABAN, |
||||
| 191 | 26924917 |
CA |
||
Hospitalisation, Dysphagia, Somnolence, |
||||
RIFAXIMIN, |
||||
| 192 | 26925054 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 193 | 26925055 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 194 | 26925319 |
AU |
1 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 195 | 26925320 |
GB |
2 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 196 | 26925484 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 197 | 26925735 |
GB |
1 | |
Hospitalisation, Treatment noncompliance, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 198 | 26925760 |
US |
30 | 1 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 199 | 26925767 |
1 | ||
Hospitalisation, |
||||
ASCIMINIB, |
||||
| 200 | 26926161 |
1 | ||
Death, Hospitalisation, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30